嘉和生物-B(06998.HK):GB263T首次人體臨牀試驗完成首例患者給藥
格隆匯5月18日丨嘉和生物-B(06998.HK)發佈公吿,GB263T(臨牀試驗編號: NCT05332574,一款創新型EGFR/cMET/cMET三特異治療抗體)的首次人體臨牀試驗(FIH)已完成首例患者給藥。
得益於集團化學、製造及控制(CMC)團隊強有力的實力保障與快速推進的執行力,GB263T在短短十二個月的時間內便按照國際化標準完成了工藝技術開發、毒理及臨牀用藥生產、臨牀試驗申請等工作,遠低於行業平均時長。此外,該品種表達量高達5-6g/L,純度高達99.5%,產品品質良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.